In a deal with Theriva Biologics potentially worth as much as $36 million, Rasayana has gained a gastrointestinal ass...
Rasayana licensed SYN-020, a gastrointestinal candidate, from Theriva Biologics in a deal potentially worth up to $36 million.
Why it mattersSYN-020's $36 million licensing to Rasayana should prompt portfolio reallocations toward gut-targeting therapeutics.